MedTrace Logo

Intravenous Immune Globulin (IVIG) Treatment Protocol in Kidney Transplant Patients

NCT00586716 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2017-01-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the clinical and laboratory observations of IVIG therapy in the highly sensitized patient. We will study the effects of patients treated with IVIG or Cytogam in combination with plasmaphoresis to modulate the immune response in highly sensitized patients. The goal is to convert a positive crossmatch to a compatible crossmatch that would allow living related transplant to take place or to shorten time on the transplant waiting list.

Conditions

Interventions

DRUG

intravenous immune globulin

0.5-2 gm/kg monthly (maximum dose of 140 gm/dose) x 4 treatments

Sponsors & Collaborators

  • Loma Linda University

    lead OTHER

Principal Investigators

  • Okechukwu Ojogho, MD · Loma Linda Universtiy Adventist Health Sciences Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2009-09-30
Completion
2009-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00586716 on ClinicalTrials.gov